Matt Henriksen

I noticed in the approval itself, it was called, let me just make sure I got my notes down, glucose range monitoring system.

That's different from the integrated continuous glucose monitoring system that the Dexcoms and the Abbott's have.

Is that something I'm diving in too deep into the difference in the classification name?

Or is that just the start of the technology and to whom the technology is approved for?

They don't need to calculate that into their... Correct.

Interesting.

And so that's also about now being in the type two non-insulin space.

It is a much larger opportunity than that insulin intensive space.

And so, you know, with that market opportunity there, it makes me think about, well, Dexcoms and Abbott's, you know, type two non-insulin intensive products, Stello and Lingo, right?

And it gets me to just basically how you order those products, because you don't need a prescription for those two.

You just go to their website and order it online.

And maybe at some point they do the pharmacy channel, but it's right now directly in their website and it's all out of pocket.

Is the Shine monitor going to be a similar commercial design for you guys?

Yeah.

Interesting.

Yeah.

Because, you know, we talked earlier about, you know, the context of the type two is very important.

Seeing those trends, making those changes, everything is important.

Yeah.

I mean, it'd be curious to see because, you know, like I said, the costs, you know, and I can easily see something along the lines of, you know, once a year before your annual contract.